Introduction
Members of the TNF receptor superfamily form a group of currently more than 20 proteins with a wide range of different functions, such as regulation of cell survival, differentiation, immune regulation and control of gene expression. Their common structural feature is the presence of cysteine-rich domains which occur in two to six repeats in their extracellular region. Among the TNF receptor-related molecules, a subgroup has been defined. These receptors are referred to as death receptors since one of their most prominent function is to induce programmed cell death. 1 Death receptors are structurally characterized by a similar intracellular region of about 80 amino acids, designated the death domain (DD), because it is required for the transmission of the cytotoxic signal. Homology searches in expressed sequence tag databases led to the identification of a number of DD-containing receptors. Currently, six different such death receptors (DRs) are known, including CD95 (also known as Fas or APO-1), TNF receptor-1, TNF receptor-related apoptosis-mediating protein (TRAMP), two receptors that bind TNF-related apoptosis-inducing ligand (TRAIL), called TRAIL-R1 and TRAIL-R2, and death receptor-6 (DR6) (Figure 1 ). While the role of TRAMP and DR6 is not well known, both the biology and the pathophysiology of the TNF and TRAIL receptors and CD95/Fas have been extensively investigated.
The cognate death ligands can be expressed by various cell types. CD95 ligand (CD95L) and TNF are mainly found in activated lymphocytes and macrophages, respectively, whereas TRAIL is expressed by various cell types. A high constitutive expression of CD95L is detected in Sertoli cells of the testis and epithelial cells of the anterior eye chamber, leading to the proposal that CD95L is responsible for the maintenance of immune-privileged sites. The triggering of CD95 by agonistic antibodies or CD95L may prevent rejection of transplanted tissues or attenuate autoimmune diseases. Our understanding of the function of CD95 and its ligand has been mainly elucidated by the finding that both molecules are mutated in mouse strains suffering from autoimmune diseases. Lpr mice which lack a functional CD95 receptor as well as gld mice which bear a mutant CD95 ligand exhibit various autoimmune phenomena resembling systemic lupus erythematosus. Defects in the CD95/CD95L system strongly disturb the immune system and result in the massive expansion of resting lymphoid cells accompanied by lymphadenopathy, splenomegaly, hypergammaglobulinemia and other signs of autoimmune disorders. In humans, a similar disease, called ALPS (autoimmune lymphoproliferative syndrome) or CanaleSmith syndrome, has been found. ALPS can be subdivided into (1) ) which impair recruitment of the FADD adapter protein, 5 (2) type II ALPS with inactivation of signaling molecules such as caspase-10, 6 and (3) type III ALPS (also termed ALD for autoimmune lymphoproliferative disease) 7 with yet to be defined molecular aberrations, presumably in further downstream signaling modules. 4 ALPS may be cured by bone marrow transplantation. 8 Interestingly, sporadic development of lymphomas has been reported in some families of ALPS patients. Nevertheless, the development of malignant disease is not a clear-cut feature of this syndrome, indicating that dysregulation of the CD95 system alone is not sufficient for development of malignancies. The contribution of other death receptors and their signal components remains to be elucidated.
Deregulation of death receptors and their signaling pathways may also contribute to other diseases as suggested for myelodysplastic syndromes (MDS) 9, 10 where CD95/Fas signaling in myeloid bone marrow precursors is disturbed. Most interestingly, increased CD95/FasL expression can be detected in myeloid blasts, erythroblasts, maturing myeloid cells, megakaryocytes and dysplastic cells from MDS patients, whereas in AML, expression may be observed in the blasts. CD95/Fas ligand expression correlated in one study with the FAB subtype groups of MDS, and also correlated directly with Schematic representation of death receptors and their neutralizing decoy receptors. Members of this subgroup of the TNF receptor superfamily are characterized by the intracellular death domain, depicted as a gray box. The two to four boxes in the extracellular part represent homologous cysteine-rich domains which mediate ligand binding and trimerization of the receptors. The TRAIL decoy receptors DcR1 and DcR2 lack an intracellular domain or contain a truncated non-functional death domain. Osteoprotegerin (OPG) and DcR3 are secreted. The commonly used terms for the different death receptors and decoy receptors are given.
the percentage of abnormal metaphases found by cytogenetic analysis. In addition, the CD95/Fas ligand expressed in MDS bone marrow was shown to inhibit the growth of clonogenic hematopoietic progenitors which could be blocked specifically by disrupting the CD95/Fas receptor/ligand interaction by the use of blocking CD95/Fas-Fc fusion protein constructs. This suggests that CD95/Fas is a key regulator of apoptosis during myelopoiesis and that the characteristic dramatic increase in apoptosis of bone marrow precursors in MDS 11 is, at least in part, due to overactivity of death ligands and their receptors in this cellular compartment. Furthermore, FasL expression in MDS bone marrow was suggested to be higher in patients who are more anemic and to correlate with red cell transfusion requirements over the subsequent course of the disease 10 although additional apoptosis pathways may contribute to disease pathogenesis. 11, 12 The impressive apoptosis-inducing properties of death receptors and their ligands promoted their application in experimental cancer therapy. In the early 1990s, experiments with agonistic human CD95 antibody showed very promising results. A single injection of an agonistic anti-CD95 antibody could mediate long-term eradication of xenotransplanted human tumors in mice. [13] [14] [15] It became, however, soon clear that such antibodies did not crossreact with the murine CD95 receptor. Thus, the considerable toxicity of CD95 triggering on non-malignant tumor cells was overlooked, but became evident when a murine-specific anti-CD95 antibody was injected into mice: these animals rapidly succumbed due to the massive liver toxicity caused by induction of apoptosis in hepatocytes. 16 New optimism came from data obtained with a novel death ligand, called TRAIL (for TNF receptor-related apoptosisinducing ligand). TRAIL has the ability to rapidly induce apoptosis in a wide variety of transformed human cell lines in vitro, yet no cytotoxicity is observed with most normal nonmalignant cells. 17, 18 The potential therapeutic activity has been demonstrated in vivo against both human breast and colon tumor xenografts grown in mice. Multiple injections of TRAIL suppressed the growth of these tumors and induced complete tumor remission in a high proportion of tumor-bearing mice. However, very recently, serious concerns were Leukemia raised when cultured normal human hepatocytes and certain other cell types were shown to be susceptible for TRAIL (see below). Nevertheless, the toxicity profile of TRAIL might be not as dangerous as in the CD95 system where apoptosis was seen in most tissues. 1, 19, 20 Thus, whether the TRAIL pathway represents the long sought after means to selectively kill tumor cells remains to be shown.
Structure and function of death receptors
Although a principal feature of death receptors is to induce apoptosis, for most receptors functions unrelated to cell death have been found. The (patho)-physiology of the prototype death receptors TNF-R1 and CD95 has been intensively studied and described in several reviews. 1, [19] [20] [21] [22] In contrast, the physiological relevance of the new death receptors is largely unknown. TRAMP, also called DR3, WSL-1, APO-3 or LARD, and the recently characterized death receptor-6 (DR6) are both structurally and functionally similar to TNF-R1, because their overexpression leads to nuclear factor-kappa B (NF-B) activation and apoptosis. [23] [24] [25] [26] [27] [28] TRAMP is abundantly expressed in thymocytes and lymphocytes and may play a role in lymphocyte development, whereas DR6 is expressed in most human tissues. The cloning of the different TRAIL receptors revealed a new apoptosis system with apparently high complexity. Two receptors, TRAIL-R1 (DR4, APO-2) and TRAIL-R2 (DR5) contain a functional death domain and can therefore signal for apoptosis. [29] [30] [31] [32] [33] [34] In addition, the TRAIL system consists of three TRAIL-neutralizing decoy receptors, called DcR1 (TRAIL-R3, TRID, LIT), DcR2 (TRAIL-R4) and osteoprotegerin (OPG, TRAIL-R5) 29, [35] [36] [37] [38] ( Figure 1 ). DcR1 contains the external TRAIL-binding region as well as a region that anchors the receptor to the membrane. But unlike the other receptors, DcR1 lacks an intracellular tail needed to spark the death pathway. DcR2 is also able to bind TRAIL but contains a truncated non-functional death domain. Finally, OPG has been found to bind and to neutralize TRAIL. 36 The molecule was originally detected as a secreted receptor dimer involved in inhibition of osteoclast differentiation. 38 In addition, OPG appears to be a decoy receptor for the TRANCE/RANK system which not only regulates osteoclast differentiation but also mediates T cell/dendritic cell (DC) costimulatory interactions and shares functional similarities with the CD40/CD154 system. The receptor RANK (receptor activator of NF-B) is expressed on myeloid osteoclast precursors, mature osteoclasts and DCs, and the ligand, RANKL (TRANCE/OPGL/ODF), is found on T cells. [39] [40] [41] Like CD40, this receptor system lacks a death domain and has so far not been implicated in the induction of apoptosis. In contrast, it may deliver not only activation and differentiation but also survival signals to DCs, osteoclasts and their precursors.
The two signaling TRAIL receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2, induce apoptosis in various cancer cells, whereas the decoy receptors, which are mainly expressed on normal cells, confer resistance against TRAIL. Furthermore, a CD95 ligand-neutralizing decoy receptor DcR3 (TR6) has been identified. 42 DcR3 lacks an apparent transmembrane sequence and is secreted. In contrast to the decoy receptors of the TRAIL system, DcR3 is expressed in tumor cells. It binds specifically two cellular ligands, CD95L and LIGHT (herpes virus entry mediator-L). 43 Thus, certain tumors may escape CD95L-and LIGHT-dependent immune-cytotoxic attack by expression of DcR3. 42, 43 It is not surprising that, in addition to the receptors, the ligands also display structural homologies, which are reflected by similar mechanisms of receptor recognition and triggering. Among the TNF-related cytokines, five ligands bind to death receptors, such as CD95L, TNF, lymphotoxin-␣ (LT␣), TRAIL and TWEAK, which was recently identified as a ligand for DR3/TRAMP. [44] [45] [46] As suggested by structural and biochemical data, all active ligands consist of three identical subunits and activate their receptors by oligomerization. 14, 47 Another common feature is that, with the exception of LT␣, all are type II transmembrane proteins. Although the ligands are synthesized as membrane-bound molecules, they also exist as soluble forms generated by rather specific metalloproteases. There is some evidence indicating that the membrane-bound and soluble forms of the ligands exert different activities and cellular functions.
Signaling
A major progress in the understanding of death receptor signaling came from the definition of protein motifs that propagate the cytotoxic signals elicited upon receptor ligation ( Figure 2 ). One proximal motif is the so-called death domain (DD), which is crucial for triggering cell death. Two other important motifs include the death effector domain (DED) and a less well-defined motif, termed the caspase recruitment domain (CARD). The DD of death receptors is required for formation of a receptor signaling complex by homophilic recruitment of adapter proteins that also contain a DD motif. As revealed by NMR spectroscopy, the DD consists of a series of ␣-helices with many exposed charged amino acids that mediate self-association of the DD following ligand binding and receptor oligomerization. 48 Important DD proteins involved in death receptor signaling include the adapters FADD (MORT-1), RIP and TRADD. FADD has a high affinity to CD95, whereas it weakly binds to the DD in TNF-R1. [49] [50] [51] TNF-R1, in contrast, binds preferentially to TRADD, which itself can then recruit FADD to the vicinity of TNF-R1. 52 TRADD, in addition, recruits the serine protein kinase RIP to TNF-R1. 53 Although RIP was initially suggested to play an important role in apoptotic signaling, it Cross-communication and putative amplification loops of apoptotic pathways. (a) One pathway (left) is induced by death receptor ligands, such as CD95L. A death-inducing signaling complex consisting of CD95L, the CD95 receptor, the adapter protein FADD and pro-caspase-8 is formed at the cell surface leading to activation of the initiator caspase-8. Caspase-8 in turn cleaves and activates the effector caspase-3. This pathway can either be amplified by caspase-8-mediated cleavage of Bid (1) and by the downstream, caspase-6-mediated cleavage of caspase-8 (1Ј) which connect this pathway to the mitochondrial apoptosome. (b) Another, death receptor-independent pathway (right) is triggered by many apoptotic stimuli, such as cytotoxic drugs, ceramide and irradiation, and leads to the loss of the mitochondrial membrane potential and release of cytochrome c into the cytosol, presumably via a Bax-dependent mechanism. Cytochrome c, together with (d)ATP, Apaf-1 and pro-caspase-9, then forms the mitochondrial apoptosome 67 leading to activation of the initiator caspase-9 followed by activation of the effector caspase-3, -6, and -7. This pathway can either be amplified by downstream, caspase-6-mediated cleavage of pro-caspase-8 (2) or by caspase-3-mediated cleavage of Bid (2Ј). DD, death domain; DED, death effector domain; CARD, caspase recruitment domain.
is more crucial for TNF-mediated NF-B activation. In a mutant cell line deficient in RIP, CD95 signaling was not affected, whereas TNF-R1-mediated NF-B activation was blocked. 54 Overexpression of most DD proteins causes cell death indicating that these molecules are involved in apoptosis signaling. In the case of FADD, transient expression of the N-terminal region was sufficient to cause apoptosis. 51 This part of FADD was therefore termed the death effector domain (DED). In contrast, overexpression of the C-terminal DD-containing part lacking the DED protected cells from CD95-mediated apoptosis and functioned as a dominantnegative mutant.
Most information regarding death pathways has been obtained from two-hybrid assays. In contrast, for CD95 the signaling complexes have been also identified in vivo. Treatment of cells with agonistic anti-CD95 antibodies and subsequent co-immunoprecipitation led to the identification of receptor-associated proteins in 2D protein gel electrophoresis. Together with the receptor these proteins form the deathinducing signaling complex (DISC). 55 Two spots were identified as differentially phosphorylated forms of FADD. Sequen-cing of the other proteins resulted in the identification of a molecule which contained two DEDs at its N-terminus that associate with the DED of FADD. 56 At its C-terminus, it had the typical catalytic domain of an ICE (interleukin-1␤ converting enzyme)-like protease and was therefore termed FLICE (FADD-like ICE). It belongs to the cysteine proteases of the caspase family and is now referred to as caspase-8. 57 Identification of caspase-8 as part of the DISC therefore connected two different levels in apoptosis pathways, the receptor with the executioner caspases mediating the terminal effector phase of apoptosis.
Overexpression of functionally inactive FADD and caspase-8 did not only block CD95, but also inhibited TNF-R1-induced signaling. This suggested that both receptors are coupled to a similar signaling complex. As mentioned above, FADD, however, does not directly bind to TNF-R1 but becomes associated upon binding of the DD-containing protein TRADD. Similarly to TNF-R1, TRAMP and DR6 can induce apoptosis and activate NF-B and bind to TRADD. 23, 24, 27 Additionally, TRAMP has been reported to interact with TRAF2, FADD and caspase-8. 23, 24 It was also found that TRAIL activates caspase-8 and the structurally similar caspase-10 (FLICE-2). 29 Whether apoptosis triggered by the two TRAIL-receptors is FADD-dependent, has been controversial. It was initially suggested that TRAIL-R1 and TRAIL-R2 do not require FADD interaction, while other reports showed that overexpression of dominant-negative FADD attenuated TRAIL-triggered apoptosis. 29, 31, 32, 34 Very recently, endogenous FADD and caspase-8 have indeed been shown to be components in the native DISC of both TRAIL receptors. [58] [59] [60] It should be noted that death receptors can recruit additional adapter proteins, such as RAIDD and RICK, which bind to death receptors and induce apoptosis upon overexpression. RAIDD carries a DD at its C-terminus, and at its N-terminus it displays homologies with the prodomain of caspase-2. Thus, it was suggested that RAIDD would engage TNF-R1 via RIP and induce caspase-2 activation. 61 Since caspase-2 (−/−) mice, however, have no defects in death receptor signaling, 62 the contribution of this pathway to TNF-R1 and CD95-mediated cytotoxicity remains unclear. It was further demonstrated that death receptors can directly trigger other signaling pathways leading to reactive oxygen formation, ceramide generation and activation of protein kinase cascades. In addition, the C-terminal portion of the adapter protein DAXX was shown to interact with the CD95 death domain, while a different region activates both the JNK kinase and apoptosis. 63 More recent studies showed that, although specifically enhancing CD95 function, human DAXX does not bind directly to CD95 but instead is found in the nucleus where it localizes to PML oncogenic domains (PODs). 64 Another report confirmed that DAXX may activate JNK signaling but challenged the view that DAXX is functionally involved in CD95 signaling under physiological circumstances. 65 Thus, a single receptor is able to trigger multiple pathways which, in addition, can participate in induction of cell death. Despite the key role of the DD, the possibility that proteins associated with other intracellular regions of the receptors contribute to the overall pattern of apoptosis cannot be excluded.
Recent studies have shown that, besides DISC-induced caspase-8 activation, mitochondria play an important role in the regulation of apoptosis. An early event in this process is the translocation of cytochrome c from the mitochondria into the cytosol, which is inhibited by anti-apoptotic Bcl-2 and homologous proteins. [66] [67] [68] In the cytosol, cytochrome c interacts Leukemia with Apaf-1 (apoptotic protease-activating factor-1), the mammalian homologue of the C. elegans cell death regulator Ced-4 69 ( Figure 2) . A second cofactor required for Apaf-1 function is (d)ATP. Binding of these two components presumably leads to a conformational change in Apaf-1 and exposes an interaction motif, the caspase recruitment domain (CARD). This region serves as protein interface by binding to caspases that have a similar domain at their N-terminus. In particular, caspase-9 is recruited and activated by Apaf-1. 70 The release of cytochrome c into the cytosol is induced by a variety of proapoptotic conditions. Since relocalization of cytochrome c is observed during TNF-R1 and CD95-mediated apoptosis, 71 the Apaf-1-controlled pathway may also be functional in apoptotic pathways triggered by death receptors. This process presumably involves a Bid-dependent pathway leading to a conformational change in the pro-apoptotic mitochondrial activator Bax.
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Initiator and effector caspases and their targets
Caspases 74 are synthesized as zymogens that contain an Nterminal prodomain followed by sequences encoding a large and a small subunit with the catalytic domain. The mature and active form of all caspases is a heterotetrameric complex composed of two large subunits and two small subunits. 75, 76 Caspases with large prodomains, eg caspase-2, -8 and -9, are thought to be involved in the initiation of the apoptotic response and are therefore called initiator caspases. Initiator caspases are directly linked to different death-inducing signaling complexes, such as the CD95/Fas signaling complex (pro-caspase-8) or the mitochondrial apoptosome (pro-caspase-9), by protein interaction motifs in their prodomains. Two general interactions have been described. Pro-caspase-8 contains two tandem death effector domains and is recruited to CD95 receptor via the adapter protein FADD, 56 whereas pro-caspase-9 contains a caspase recruitment domain and is specifically localized to the mitochondrial death-inducing signaling complex via the adapter protein Apaf-1. 77 Caspases harboring a short prodomain, eg caspase-3, -6 and -7, are activated by initiator caspases and are mainly responsible for the cleavage of downstream cellular targets. Hence, these caspases are called effector caspases. Members of the caspase family build up the core complex of the death machinery and are involved in the signaling processes as well as in the execution processes of apoptotic cell death. There are several cellular structures which have to be targeted during the execution of apoptotic cell death. In principle, caspase-mediated cleavage should result in different effects, such as (1) a halt of cell cycle progression, (2) disabling of repair mechanisms, (3) disassembly of molecular structures, (4) cell detachment, and (5) tagging of the apoptotic cell for engulfment by phagocytes. 78 Experimental data showed that not all roads to cell death depend on the activation of caspases. Caspase-independent cell death includes necrosis but also some forms related to apoptosis. For example, treatment of Molt-4 cells with low concentrations of membrane-permeable ceramide analogues clearly induced apoptotic cell death which was accompanied by cleavage of PARP and inhibited by Bcl-2. In contrast, high concentrations of these synthetic ceramides induced necrosis. This form of cell death was not blocked by Bcl-2 overexpression and PARP cleavage was not observed. 79 There are also reports that death receptors cannot only induce apoptosis but, in addition, necrotic cell death [80] [81] [82] which might be as important as the induction of apoptosis, especially with regard to cancer therapy. 83 Experiments with cells from Apaf-1 and caspase-3 knockout mice revealed the existence of two distinct pathways leading to nuclear apoptosis. 84 One caspasedependent pathway targets caspase-activated DNase (CAD), while another pathway is caspase-independent and mediated by the mitochondrial apoptosis-inducing factor (AIF). 85 In this line, it has been recently demonstrated that release of AIF into the cytosol of activated blood T lymphocytes may represent a caspase-independent, reversible commitment phase to apoptosis. 86 Furthermore, a new apoptosis signaling pathway originating at the endoplasmic reticulum and involving caspase-12 has been described. 87 However, this form of cell death seems to be independent from death receptors and is activated under relatively rare circumstances, such as the massive disturbance of protein synthesis or aberrant protein expression. 67 Its relevance still has to be determined in more detail.
The two principal signaling pathways of apoptosis via death receptors and mitochondria have been well established and intensive experimental efforts over the past years have elucidated their molecular components. [88] [89] [90] Although both pathways use distinct signaling components they converge at the level of the effector caspase-3 ( Figure 2 ). Several lines of evidence demonstrated an interconnection of the pathways. Bid, a BH3 domain-containing proapoptotic Bcl-2 family member, is a substrate of caspase-8 in the CD95 signaling pathway. 91 Following caspase cleavage, truncated Bid translocates to mitochondria and induces the release of cytochrome c, thereby amplifying the apoptotic signal (Figure 2) . Furthermore, by reconstituting the apoptosome in a cell-free system it was shown that caspase-8 activation may occur downstream of caspase-3 in the cytochrome c-initiated mitochondrial caspase cascade. 92 Thus, caspase-3 can participate in a feedback amplification loop, at least in vitro. Results from our laboratory confirmed these in vitro data in intact cells. We could demonstrate CD95-independent processing and activation of caspase-8 in drug-treated B lymphoid cells. Time course experiments revealed that processing of caspase-8 was preceded by loss of the mitochondrial membrane potential and activation of caspase-3. Activation of caspase-8 was blocked by preincubation of the B lymphoid cells with the caspase-3 specific inhibitor zDEVD-fmk. 93 Thus, in drug-induced apoptosis in B lymphoid cells the molecular order is represented by the hierarchical activation of mitochondria, caspase-3 and downstream caspase-8. In this system caspase-8 functions as an amplifying executioner rather than as an initiator caspase (Figure 2 ). Interestingly, a short cut of the drug-induced amplification loop has been described which is triggered by caspase-3-mediated cleavage of Bid. This suggests that Bid can also be cleaved by caspases other than caspase-8. 94, 95 Taken together, it seems that a tight cross-communication between the main death pathways exists under physiological as well as under pathological conditions. The usage of such additional pathways and the multiple amplification loops by death receptors remains to be elucidated but may play a decisive role in determining the final outcome of death receptor signaling.
Survival pathways
Under certain circumstances, ligation of death receptors after challenge with death ligands might also lead to induction of survival pathways. 96 This is best documented for TNF and its 75 kDa receptor TNF-R2. Binding of TNF activates the transcription factor NF-B, which in turn suppresses apoptosis 97 and may antagonize TNF receptor-triggered cell death. 98 Further experiments identified TNF-R-associated factor 1 (TRAF1), TRAF2 and the inhibitor of apoptosis proteins cIAP1 and cIAP2 as gene targets of NF-B transcriptional activity. 99 Interestingly, cIAPs are able to function as both upstream and downstream effectors of TNF-induced survival pathways. Evidence was provided that c-IAP1 and c-IAP2 are recruited to the TNFR2-TRAF signaling complex and thereby promote NF-B activation. 100, 101 In addition, it is generally accepted that some members of the IAP family block apoptotic events by direct inhibition of distinct caspases. 102, 103 In endothelial cells, the Bcl-2 family member A1 is induced by TNF in a NF-Bdependent manner and functions as a cytoprotective factor that maintains mitochondrial viability and function. 104 Thus, TNF-induced survival pathways obviously interfere with cell death signaling at different levels of the apoptotic machinery, eg at the death-inducing signaling complex, the mitochondria and the effector caspases.
Death ligands in cancer therapy
Due to their ability to kill cancer cells and to eradicate xenotransplanted tumors, some of the death receptors have been considered as potential targets in cancer therapy. In addition, treatment of autoimmune disorders or prevention of transplant rejection by death receptor targeting is under investigation. In the late 1980s, clinical phase I and II trials were performed with TNF for the treatment of various cancers, eg hairy cell leukemia and solid tumors. The results, however, were disappointing and showed no significant antitumor activity, but were associated with a high grade of systemic toxicity (eg cytokine release syndrome, hepatotoxicity, thrombocytopenia). 105, 106 As a consequence, the systemic application of TNF was abandoned in cancer therapy.
At the end of the 1980s, the impressive antitumor activity of agonistic monoclonal antibodies against CD95 in murine xenotransplant models of human tumors established that apoptosis induction might be employed for cancer therapy. [13] [14] [15] A single injection of antibodies against human CD95 resulted in cure from xenotransplanted human tumors in immunodeficient nude and SCID mice. Thus, stimulating the CD95 receptor with agonistic monoclonal antibodies or CD95L was evaluated as a novel approach for antitumor therapy. The use of a species-specific monoclonal anti-murine-CD95 antibody revealed, however, considerable systemic toxicity, in particular hepatotoxicity. 16 Efforts are still being made to reduce the systemic toxicity, for instance by reducing CD95 expression in liver cells prior to CD95 agonistic therapy. CD95 triggering either by agonistic antibodies or its ligand revealed that a broad variety of non-malignant cells are susceptible to CD95-triggered apoptosis. 1, 19, 20 This may lead to immune suppression, since physiological signaling via CD95 is involved in immune tolerance both in the T and B cell compartment. [108] [109] [110] [111] Interestingly, co-stimulatory signals such as via B7/CD28 112, 113 or CD2/CD58, eg by dendritic cells, 114 can overcome this deleterious effect of immune cell depletion by death receptor signaling. Most studies examining non-malignant cells have been performed by the use of agonistic antibodies, and rather rarely recombinant CD95L has been employed. For the trimerization and activation of CD95 downstream signaling, this difference might not be trivial. A number of reports showed that the death-inducing activity of such antibodies is different from the action of the natural ligand. In addition, the soluble form of CD95L that is produced by proteolytic cleavage is a less potent inducer of apoptosis than its membrane-bound form. 115 More recently, TRAIL/APO-2L was shown to be selectively cytotoxic for tumor cells but exerted only minimal or no toxicity in normal tissues of mice and primates. Therefore, TRAIL was considered as a new agent with great potential for its in vivo anticancer effect, either alone or in combination with drugs. It has been demonstrated that tumor cells that are resistant to TRAIL can be sensitized by subtoxic concentrations of drugs and cytokines, and the sensitized tumor cells are significantly killed by TRAIL. 17, 116 Although TRAIL is expressed on a wide range of tissues, co-expression of the decoy receptor proteins DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4) inhibits cell death due to their absent or truncated cytoplasmic death domains. Initially, expression of these decoy receptors was held responsible for the observed tumor cell-specific killing by TRAIL.
Although TRAIL has been found to kill a wide variety of tumor cells, very recently, serious concerns were raised about the use of TRAIL in cancer therapy. 117 Its safety has been challenged by a report that showed induction of apoptosis by TRAIL in cultured human hepatocytes. 118 The study compared the sensitivity of hepatocytes from rats, mice, rhesus monkey and humans. It was found that while the animal hepatocytes were not affected by the drug, TRAIL did cause significant death in normal liver cells of humans. The reason for the species specificity of TRAIL liver toxicity is difficult to explain, and it is possible that hepatocytes of mice and monkeys produce a protective factor that is absent in human cells. Certainly, these results are a warning and may suggest that substantial liver toxicity might result if TRAIL is used as a systemic drug in clinical trials. It has also been observed that recombinant TRAIL induces apoptosis in normal living brain slices and erythropoietic cells, 119, 120 while another report claims that CFU-GM or BFU-E colony formation in vitro is unaffected by TRAIL. 121 In the brain, the susceptible cells were identified as neurons, oligodendrocytes, astrocytes and microglial cells. 119 Altogether, the current data suggest that a potential use of TRAIL in cancer therapy has to be considered with caution and awaits further in vivo studies.
Apart from toxicity, another problem arises regarding resistance mechanisms in cancer cells. Tumor cells can be resistant to death receptor-induced apoptosis, either due to the expression of decoy receptors or the inactivation or loss of the targeted receptor or distal signaling cascades. Mutations in CD95 have been described in T-lineage acute leukemias 122, 123 or Burkitt lymphoma and loss of caspase-8 expression was found in childhood neuroblastomas. 124 In addition, clonal variability in CD95/Fas expression has been demonstrated to be a major determinant in the development of resistance against death signaling via the CD95/Fas receptor. 125 Furthermore, homozygous deletion of death receptor DR4 gene may lead to TRAIL resistance. 126 Another mechanism for cellular resistance towards death receptor-induced apoptosis is the activation of survival signaling pathways, for instance via upregulation of NF-B or members of the IAP family or FLIP proteins. 127 Other possible causes include the deregulation of the mitochondrial apoptosome, 67 especially the members of the Bcl-2 family which may show considerable intra-and interdisease variability, eg in lymphoma, 128 and may shift to an apoptosis-refractory profile when resistance develops. 129 Recently, an IAP-neutralizing and therefore apoptosis-promoting mitochondrial protein, termed Leukemia Smac/Diablo, has been identified that obviously plays a critical role in antagonizing the caspase-inhibitory effect of IAPs. 130, 131 The role of Smac in tumor biology is as yet unclear but inactivation of this novel player could also result in a resistant phenotype. Thus, death receptor-targeted therapeutic approaches may encounter similar problems as conventional chemo-or radiotherapy. Nevertheless, the resistance profile may be quite different and cross-resistance may be a rare event.
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Death receptors in radio-and chemotherapy
An exciting finding is that death receptors of the TNF, CD95 and TRAIL systems appear to cooperate with radiation-and drug-induced cell death. 116, [133] [134] [135] [136] [137] Radiation and chemotherapy upregulate CD95 in different tumor cells via a p53-dependent mechanism. 138 The TRAIL receptor KILLER/DR5 is induced by DNA damage and also appears to be regulated by the tumor suppressor gene p53, 139 which may at the same time be counteracted by negative feedback induction of the TRAIL decoy receptors by p53. 140, 141 Both CD95 and KILLER/DR5 therefore provide potential links between DNA damage-mediated activation of p53 and the caspase cascade. 142 There is a considerable amount of crosstalk between the two signaling pathways (death receptor-vs cytotoxic druginduced apoptosis; see also Figure 2 ). Therefore, the pretreatment of cancer cells with TNF␣, CD95L or TRAIL may sensitize tumor cells to chemotherapy or radiation and vice versa. 135 Unfortunately, deregulation of the p53/p14ARF-pathway which is a frequent event in cancer [143] [144] [145] may therefore also contribute not only to drug resistance but may also lead to impaired expression of death receptors and their signaling pathways, 145 which may result in additional defects in the regulation of cell death and survival.
This striking interaction between drug-and death receptorinduced apoptosis led to the hypothesis that these receptors may be directly involved in drug-induced apoptosis. [146] [147] [148] Death ligands and receptors may be induced during drugtriggered apoptosis (see above).
A number of reports, however, showed that cell death induced by anti-cancer drugs or irradiation is completely independent from death receptor signaling. 93, [149] [150] [151] This also holds true for the activation of caspase-8 during drug-induced apoptosis. 152 In contrast to the death-receptor/FADD-dependent pathway, caspase-8 activation is triggered in this situation by a receptor-independent, post-mitochondrial mechanism downstream of caspase-3 and functions as an amplifying executioner caspase during drug-induced apoptosis. 93 Neither does it depend on receptor-independent FADD-mediated signaling, as recently suggested, for ganciclovir-induced cell death, since overexpression of a dominant negative FADD adapter protein lacking the DED domain for caspase-8 recruitment cannot block drug or irradiationinduced cell death. 93, 151, 152 Thus, drug-induced apoptosis definitively does not depend on CD95/Fas or other death receptors. The caspase-8 activation observed in various systems of anticancer therapy-induced cell death 93, 149, [152] [153] [154] therefore represents a downstream signaling event which may, nevertheless, be involved in the amplification of apoptosis execution.
As described above, death receptor signaling may contribute to drug-induced death and the pathways may cross-sensitize for each other. However, inactivation of death receptor signaling cannot prevent drug-induced apoptosis. Thus, path-ways apart from death receptors such as the mitochondrial signaling cascade are certainly the decisive steps for the execution of cell death in cancer therapy.
Conclusions
Death receptor signaling plays an important role in mediating apoptosis of non-malignant cells to maintain tissue homeostasis. This has been demonstrated most convincingly in immune-competent cells and may explain the toxicity profile when death ligands, such as CD95L or TRAIL, are employed in cancer therapy. The potency of such death ligands to kill cancer cells is impressive but the danger to elicit deleterious systemic toxicity cannot be neglected. The ability of TRAIL to induce apoptosis in normal primary hepatocytes, cells of the CNS, lymphocytes and erythropoietic cells requires special attention and should warn researchers to proceed with great caution into TRAIL clinical trials. However, there remains optimism: apoptosis by death receptors can be modulated and the ongoing progress in elucidating their signaling cascades may help to define survival signals which may be utilized to save normal cells from toxic side-effects, while selectively targeting cancer cells to the 'magic bullets' of death ligands.
